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Abstract
Two mutations in FGFR3, G380R and G375C are known to cause achondroplasia, the most common form of human
dwarfism. The G380R mutation accounts for 98% of the achondroplasia cases, and thus has been studied extensively. Here
we study the effect of the G375C mutation on the phosphorylation and the cross-linking propensity of full-length FGFR3 in
HEK 293 cells, and we compare the results to previously published results for the G380R mutant. We observe identical
behavior of the two achondroplasia mutants in these experiments, a finding which supports a direct link between the
severity of dwarfism phenotypes and the level and mechanism of FGFR3 over-activation. The mutations do not increase the
cross-linking propensity of FGFR3, contrary to previous expectations that the achondroplasia mutations stabilize the FGFR3
dimers. Instead, the phosphorylation efficiency within un-liganded FGFR3 dimers is increased, and this increase is likely the
underlying cause for pathogenesis in achondroplasia. We further investigate the G346E mutation, which has been reported
to cause achondroplasia in one case. We find that this mutation does not increase FGFR3 phosphorylation and decreases
FGFR3 cross-linking propensity, a finding which raises questions whether this mutation is indeed a genetic cause for human
dwarfism.
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Introduction
Receptor tyrosine kinase (RTK)-mediated signaling regulates
vital cellular processes such as cell growth, differentiation, and
motility [1–5]. The activation of RTKs is initiated with the
phosphorylation of specific tyrosines in their intracellular kinase
domains [6,7]. For phosphorylation to occur, the kinase domains
of two RTKs need to be in close proximity, and the orientation
and the positioning of the kinases with respect to each other need
to be tightly controlled to ensure optimal enzymatic activity. The
close approach of the kinase domains is regulated by the
propensities of RTKs to form dimers in the plasma membrane,
and is modulated by ligand binding to RTK extracellular domains
[8]. Specific receptor-receptor and receptor-ligand interactions in
the dimer impose structural constraints and ensure the correct
signaling-competent orientation of the kinase domains [9].
Disregulation of the processes that control RTK activation leads
to pathologies [10–13]. Many single amino acid pathogenic RTK
mutations have been identified, and the molecular mechanism
behind these pathologies has been investigated [14–21]. While the
progress in this field has been impressive, still questions remain as
to how RTK mutations cause disease. For instance, it is not yet
known why one group of mutations in an RTK causes the same
phenotype, while another group of very similar mutations in the
same RTK causes a distinctly different phenotype. For instance,
three different mutations in FGFR3, G346E, G375C, and G380R
have been linked to achondroplasia (ACH), the most common
form of human dwarfism, while several other mutations in the
same receptor (R240C, R248C, S249C, 370C, S371C, Y373C,
and K650E) cause the much more severe and lethal thanatophoric
dysplasia type 1 (TD1) [10,11,22].
Thus far, the effect of FGFR3 mutations linked to phenotypes of
different severities have been compared and rank-ordered, and
mutations associated with more severe phenotypes have been
shown to have a more profound effect on FGFR3 signaling. For
instance, mutations associated with TD1 have been shown to
activate FGFR3 to higher extent than mutations causing ACH
[23]. However, the effect of mutations causing the same phenotype
has not been compared in order to determine if they activate the
receptors to the same, or to variable, extents, and whether the
mechanism of over-activation leading to a particular phenotype is
always the same.
To start addressing this question, here we investigate the effect
of the G375C mutation, linked to ACH, on FGFR3 phosphor-
ylation and cross-linking, and we compare the results to previously
published results for the G380R ACH mutant. The comparison is
carried out over a wide range of ligand concentrations, in order to
gain insight into the molecular mechanism that underlies the
pathology. We observe that the G375C mutation increases
FGFR3 phosphorylation in the absence of ligands and at low,
but not at high, ligand concentrations, similarly to the G380R
mutation. The dimerization propensity of FGFR3 is not affected
by the G375C mutation, as inferred from cross-linking experi-
ments. Our results demonstrate that the two achondroplasia
mutations, G375C and G380, have the same effect on FGFR3
activity, supporting the idea that identical degrees and mecha-
nisms of over-activation lead to identical phenotypes.
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G346E. While this mutation is often mentioned in the literature as
a genetic cause for ACH [12,24–29], there is a single report of a
connection between this mutation and ACH [30]. The effect of
this mutation on FGFR3 activation has not been studied thus far.
Here we perform biochemical characterization of the G346E
mutant and we show that the G346E mutation does not increase
FGFR3 phosphorylation, a finding which raises doubts whether
this mutation is indeed a genetic cause for human dwarfism.
Materials and Methods
Plasmids
The FGFR3/WT plasmid was a generous gift from D. J.
Donoghue, University of California, San Diego. The G375C and
G346E mutations were created using the QuickChangeH XL site-
directed mutagenesis kit (Stratagene, CA). All the plasmids were in
the pcDNA 3.1(+) vector. Successful incorporation of the
mutations was confirmed by sequencing provided by Genewiz
(Germantown, MD).
Western Blots
Human embryonic kidney cells (HEK 293 from ATCC) were
transfected with plasmids encoding FGFR3/WT, FGFR3/G375C
and FGFR3/G346E using FuGENE HD (Roche Applied Science)
according to the manufacturer’s protocol. Cells were cultured in
normal medium for 24 h following transfection, and were then
starved in serum-free medium for 24 h as previously described
[17,31–34]. The effect of the ligand was monitored by incubating
the cells in medium supplemented with fgf1 (Millipore, MA).
Different concentrations of fgf1, ranging from 50 to 2500 ng/ml,
were added to the serum-free medium. After incubating for
10 min with ligand, cells were lysed as described [17,31–33], and
analyzed using Western blotting. FGFR3 expression and phos-
phorylation were probed with anti-N-FGFR3 (H-100) antibodies
(sc-9007, Santa Cruz Biotechnology) or anti-P-FGFR antibodies
(anti-Tyr-653/Tyr-654, Cell Signaling Technology), respectively,
followed by anti-rabbit HRP-conjugated antibodies (Promega).
The Western blot films were scanned and processed with
ImageQuant TL. At least three sets of experiments were
performed to determine the averages and the standard deviations.
The loading of the gels was adjusted such that all the band
intensities were within the so-called linear range, such that the
staining intensities were proportional to the protein concentration
[17].
Cross-linking
Dimeric receptors were cross-linked with a membrane-imper-
meable linker (BS
3, bis(sulfosuccinimidyl) suberate, Pierce).
Twenty four hours after transfection, cells were incubated with
2 mM cross-linker for 30 min at room temperature and then
quenched in 20 mM Tris-HCl for 15 min. After a rinse with ice-
cold PBS, the cells were lysed, and the receptors were detected
using Western blotting. The cross-linked fraction was calculated as
SD/S=SD/(SM+SD), where SD is the intensity of the cross-linked
band, and SM is the intensity of the monomeric band [32].
Statistical Analysis
All experiments were repeated at least three times to determine
the averages and the standard deviations. Student t-test was used
to compare the measurements to a null hypothesis for statistical
significance, as previously described [33,34]. The p-value cutoff
for significance was determined as 0.017 using the Bonferroni
correction for multiple comparisons.
Results
Effect of the G346E and G375C mutations on FGFR3
expression pattern in HEK 293 cells
HEK 293 cells were transfected with 2 mg of DNA encoding
FGFR3/WT, FGFR3/G346E or FGFR3/G375C using Fugene
HD. 24 hours after transfection, cells were starved in serum-free
medium and lysed. The cell lysates were subjected to Western
blotting. The expression of wild type FGFR3 and the two mutants
was probed using anti-N-FGFR3 antibodies. Ten independent
experiments were performed, with two representative results
shown in Figure 1A. We observe two bands reactive to the anti-
N-FGFR3 antibodies in all cases. As discussed in previous
publications [33–35], the top band corresponds to the fully
glycosylated mature 130-kDa FGFR3 form, which is located
predominantly in the plasma membrane. The lower band
corresponds to the 120-kDa FGFR3 form, which is sensitive to
endo-b-N-acetylglucosaminidase H and is found in the endoplas-
mic reticulum/cis-Golgi. In Figure 1, we see that the transient
expression levels of the two mutants and the wild-type are
somewhat different in each experiment under identical transfec-
tion conditions, which can be expected for transient transfection.
The variation of the expression of the 120 kDa form is more
pronounced than the variation in the 130 kDa form expression.
To quantify the expression of the 130 kDa forms of the wild-type
and the two mutants, we measured the intensities of the 130 kDa
bands using Image Quant, normalized all the intensities with
respect to the wild-type intensity, and averaged the results from the
10 independent experiments. The results, shown in Figure 1B,
demonstrate that neither of the two mutations affects the
expression of mature FGFR3 in HEK 293 cells in a statistically
significant way (p values: 0.44 and 0.40 for the G346E and the
G375C mutations, respectively). In Figure 1B we also show
published results for the G380R mutant (p value: 0.33). These
results demonstrate that the G380R mutation does not affect the
expression of mature FGFR3, either [35].
Close inspection of the FGFR3/G375C Western blot results in
Figure 1 reveals a weak, but always visible, third band reactive to
anti-N-FGFR3 antibodies. Based on molecular weight, this band
should correspond to the unglycosylated 98-kDa receptor. This
finding suggests that a small portion of FGFR3/G375C fails to be
modified/glycosylated and is likely trapped inside the cells.
Response of the G346E and G375C mutants to the ligand
fgf1
Next we characterized the response of the two FGFR3 mutants
to different concentrations of fgf1. HEK 293 cells were transfected
with plasmids encoding FGFR3/WT, FGFR3/G346E or
FGFR3/G375C. Different concentrations of fgf1, ranging from
50 to 2500 ng/ml, were added to the serum-free medium. After
incubation for 10 min with ligand, cells were lysed and analyzed
using Western blotting. The receptors were stained with anti-N-
FGFR3 (H-100) antibodies or anti-P-FGFR antibodies. The anti-
P-FGFR antibodies used were anti-phospho-Tyr-653/Tyr-654
antibodies (Cell Signaling), generated to recognize phosphorylated
Tyr-653 and Tyr-654 in FGFR1. Since the amino acid sequences
of FGFR1 and FGFR3 in the vicinity of these two tyrosines are the
same, it also specifically recognizes the analogous Tyr-647 and
Tyr-648 in FGFR3 [35].
Three independent experiments were performed while varying
the ligand concentration. One representative film is shown in
Figure 2A. Only the mature FGFR3 130 kDa form, expressed
predominantly on the plasma membrane, responds to the ligand,
while the lower molecular weight FGFR3 located in the
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upon ligand titration. The intensities of the 130 kDa anti-N-
FGFR3 and anti-P-FGFR bands were quantified, and their ratio
yielded the relative phosphorylation level of the receptors. In
each individual experiment, the relative phosphorylation level
of wild type FGFR3 in the absence of ligand was assigned the
value of one, and all the phosphorylation levels were scaled
accordingly and plotted in Figure 2B. We see that in the absence
of ligand, the phosphorylation of the G375C mutant is higher
than the phosphorylation of the wild-type and the G346E
mutant. All phosphorylation levels increase with ligand concen-
tration, while the difference between the mutants and the wild-
type decreases.
In Figure 2C, we plot the ratio of the mutant and wild-type
phosphorylation levels, as a function of ligand concentration, while
also including previously published data for the G380R mutant
[35]. We see that in the absence of ligand, the phosphorylation of
both the FGFR3/G375C and the FGFR3/G380R mutants is
about 2.5 times higher than that of the wild type. This difference is
statistically significant (p-values for the G375C/WT and G380R/
WT comparisons are 0.015 and 0.001 respectively). As more
ligand is added, the difference between these mutants and the wild
type gradually decreases. On the other hand, the FGFR3/G346E
mutant does not show any increase in phosphorylation, as
compared to wild type FGFR3 (p=0.35). When the concentration
of ligand is above 500 ng/ml, there is no statistical difference
between the phosphorylation of FGFR3/G346E, FGFR3/
G375C, FGFR3/G380R and FGFR3/WT (p values: 0.82, 0.46
and 0.45 for the G346E/WT, G375C/WT and G380R/WT
comparisons, respectively).
Effect of the G346E and G375C mutations on FGFR3
cross-linking
Next we used chemical cross-linking to gain insight into the
effect of the mutations on FGFR3 dimerization. HEK 293 cells
were transfected with plasmids encoding FGFR3/WT, FGFR3/
G346E or FGFR3/G375C. Cells were starved for 24 hours, and
stimulated with high concentration of fgf1. Cells that were not
stimulated with ligand were used as controls. BS3, a membrane
impermeable linker, was used to covalently link the FGFR3
dimers on the plasma membrane. Cells were lysed and the
lysates were analyzed using Western blotting. A typical Western
Figure 1. FGFR3 expression patterns in HEK 293 cells. Cells were transfected with 2 mg/well of DNA encoding FGFR3/WT, FGFR3/G346E, or
FGFR3/G375C. 24 hours after transfection, cells were starved in serum-free medium, followed by cell lysis. The cell lysates were subjected to Western
blotting, and FGFR expression was probed using anti-N-FGFR3 antibodies. A. Two representative blots, showing the expression of FGFR3/WT, FGFR3/
G346E and FGFR3/G375C. B. Quantification of the expression of the 130 kDa mature FGFR3, based on results from ten independent experiments.
There are no statistical differences between the expressions of the wild-type and the three mutants (p.0.017, see text). Data for the G380R mutant
are from [35].
doi:10.1371/journal.pone.0034808.g001
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calculated as SD/S=SD/(SM+SD), where SD is the intensity of
the cross-linked band, and SM is the intensity of the monomeric
band. The results are shown in Figure 3B, together with
previously published results for the G380R mutant [35].
Figure 3B demonstrates that in the absence of ligand, the
cross-linked fractions of FGFR3/G375C, FGFR3/G380R and
FGFR3/WT are very similar (p-values: 0.24 and 0.20 for the
G375C/WT and the G380R/WT comparison, respectively),
whereas the FGFR3/G346E cross-linked fraction is lower than
wild type (p=0.0009). Upon the addition of fgf1,a l lt h r e e
receptors show a moderate increase (,50% to 100%) in cross-
linked fraction. In the presence of ligand, the cross-linked
fraction for wild type FGFR3 and the G375C and G380R
mutants remain similar (p-values: 0.2 and 0.74 for the G375C/
WT and the G380R/WT comparison, respectively), and the
G346E cross-linked fraction remains lower (p=0.005). The
results indicate that none of the three ACH mutations increases
FGFR3 crosslinking, and thus the dimerization propensity of
FGFR3. Therefore, the increase in phosphorylation of the
G375C or G380R mutants, shown in Figure 2, is likely not due
to increased receptor dimerization.
Discussion
The physical basis behind FGFR3 disregulated signaling
in ACH
Achondroplasia is a bone-growth disorder with phenotypic
features which include short arms and legs, and a large head with
prominent forehead [36,37]. It is often caused by a G380R
mutation in the transmembrane domain of FGFR3, a receptor
which mediates pro-differentiation signals in chondrocytes [38].
The G380R mutation has been shown to increase FGFR3
phosphorylation and thus shorten the proliferative phase in
chondrocyte development, but the cause for the increased receptor
phosphorylation is under debate. Webster and Donoghue
proposed that the G380R mutation enhances FGFR3 dimeriza-
tion, likely due to hydrogen bonding of the mutant R380 to the
neighboring receptor in the dimer [39]. However, He et.al showed
that while FGFR3 phosphorylation is increased due to the
mutation, FGFR3 cross-linking and dimerization propensities are
not affected by the mutation [35]. Instead, the cross-phosphory-
lation efficiencies within the unliganded FGFR3 dimers are
increased [35]. Based on these results, and on a molecular model
of FGFR3 TM domain created with the program CHI [16,40], it
has been proposed that the G380R mutation introduces a
Figure 2. Effect of the achondroplasia mutations on FGFR3 phosphorylation. HEK 293 cells were transfected with plasmids encoding
FGFR3/WT, FGFR3/G346E and FGFR3/G375C. Different concentrations of fgf1, ranging from 50 to 2500 ng/ml, were added to the serum-free
medium. After incubating for 10 min with ligand, cells were lysed and analyzed using Western blotting. A. A typical Western blot result. FGFR3 was
detected with anti-N-FGFR3 (H-100) antibodies (bottom) or anti-P-FGFR antibodies (top). Lanes 1: FGFR3/WT, Lanes 2: FGFR3/G346E, Lanes 3: FGFR3/
G375C. B. The relative phosphorylation levels of the receptors were calculated by dividing the anti-P-FGFR staining intensities by the anti-N-FGFR3
staining intensities. The phosphorylation levels increase with ligand concentration. C. The phosphorylation levels of FGFR3/G375C, FGFR3/G346E and
FGFR3/G380R were divided by that of FGFR3/WT. The G380R data are from [35].
doi:10.1371/journal.pone.0034808.g002
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their phosphorylation efficiencies and ultimately increasing
FGFR3 phosphorylation in the absence of ligand.
The G380R mutation accounts for about 98% of the ACH
cases. The other 2% are attributed to the G375C mutation in
FGFR3 [11]. Since this is a mutation to cysteine, it can be
expected to increase the stability of FGFR3 dimers due to the
formation of a disulfide bond. Here we demonstrate, however, that
the mutation does not increase FGFR3 cross-linking, and thus we
observe no evidence for dimer stabilization due to the formation of
disulfide bonds. Similarly to the G380R mutation, we see that the
phosphorylation of the G375C mutant is increased at low ligand
concentrations, but the mutation does not affect FGFR3
phosphorylation at high ligand concentrations. Thus, the G375C
mutation must increase the receptor phosphorylation probability
within unliganded FGFR3 dimers. In other words, it is easier to
phosphorylate Y647 and Y648 within the mutant unliganded
dimer than within the wild-type unliganded dimer. The most likely
reason for this difference in phosphorylation is a difference in the
structure of the unliganded dimer. We thus propose that the
G375C achondroplasia mutation induces a structural change in
the unliganded dimer, similarly to the G380R mutation.
A published model of the wild-type dimer structure, created
with the program CHI, predicts that Glycine in position 375 does
not face the dimer interface and is exposed to lipids [41].
Substitution of Glycine with cysteine at position 375 shows that the
two Cysteines in the dimer are far apart and cannot be expected to
form a disulfide bond [41]. Our data are consistent with this
molecular model because we do not observe an increase in the
number of dimers due to the G375C mutation, as inferred from
cross-linking experiments. Our data also suggests, however, that
the structure of the FGFR3 TM domain dimer is perturbed due to
the mutation, and this perturbation of unknown nature affects the
activity of the kinase domain. The G380R mutation has been
proposed to induce a rotation in the TM dimer interface [35].
Since the phosphorylation increase is identical due to these two
achondroplasia mutations, it can be speculated that a similar
structural change may be taking place in the presence of the
G375C mutation.
Our work is consistent with previous studies which have
reported increased phosphorylation of the G375C mutant, as
compared to wild-type [19]. Furthermore, the lack of disulfide
bond-mediated stabilization that we observe here is consistent with
a previous FRET-based study of the dimerization of isolated
FGFR3 TM domains in lipid bilayers [41]. On the other hand,
our cross-linking results for the FGFR3/G375C mutant are
different from previous work done by Adar et.al, who observed
increased FGFR3 cross-linking due to the G375C mutation [19].
This difference may be due to the experimental methods used: for
instance, Adar et al assayed cross-linking after immunoprecipita-
tion, while here we do not use immunoprecipitation.
Here we observe that FGFR3 phosphorylation in the absence of
ligand increases 2.5 times due to the G375C and G380R
mutations. The effect is greatest in the absence of ligand and the
mutation-induced difference in phosphorylation decreases as more
ligand is added. Thus, a question arises if an effect of this
magnitude can be responsible for a pathological phenotype. It is
possible that the effect is amplified due to defects in mutant FGFR
downregulation. It has been shown that the downregulation of
FGFR3 mutants linked to skeletal dysplasias is compromised, and
this effect prolongs the time that they signal [10,42–44].
Importantly, the relative magnitudes of these processing defects
have been shown to be proportional to the phosphorylation of the
mutants: the higher the phosphorylation, the longer the lifetime of
the active FGFR3 dimers in the cell [10,43,45]. Such downreg-
ulation defects should, ultimately, increase the concentrations of
the mutants in the cell, as compared to the wild-type. We did not
see statistically significant differences in receptor concentrations in
our experiments, which may be due to the fact that in this study all
receptors are overexpressed. We note, however, that we observed
an un-glycosylated band for the FGFR3/G375C mutant, which is
not observed for wild-type FGFR3 or other FGFR3 mutants.
Thus, it is possible that the FGFR3/G375C mutation interferes
with the maturation and trafficking of the receptors. The intensity
Figure 3. Effect of the achondroplasia mutations on FGFR3 cross-linking. HEK 293 cells were transfected with 2 mg DNA per well. 24 hours
after transfection, cells were starved in serum-free medium for 24 hours, followed by ligand addition, BS
3 crosslinking, and lysis. A. A typical Western
blot result. Lane 1: FGFR3/WT, Lane 2: FGFR3/G346E, Lane 3: FGFR3/G375C. B. Cross-linked fractions, calculated as SD/S=SD/(SM+SD), where SD is the
intensity of the cross-linked band, and SM is the intensity of the monomeric band. The stars indicate statistical significance (p,0.01, see text).
doi:10.1371/journal.pone.0034808.g003
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and thus this effect appears very modest.
G346E is not a gain-of-function mutation
The G346E mutation in FGFR3 has been reported to cause
achondroplasia [30], and is often cited in the literature as a genetic
cause for the disorder [12,24–29]. However, there are no
biochemical studies of the effect of this mutation on FGFR3
phosphorylation in the literature. Here we studied the effect of the
G346E mutation on FGFR3 signaling in HEK 293 cells, and we
showed that the mutation does not increase FGFR3 phosphory-
lation. This conclusion contradicts the expectation that G346E is a
gain-of-function mutation. Since there is a single report of a link
between this mutation and ACH [30], our findings raise doubts
about its validity. While the observed decrease in cross-linking for
the G346E mutant warrants further investigation, it is difficult to
envision how the decrease in cross-linking may be related to the
disorder. The activation data demonstrate that the G346E
mutation is not a gain-of-function mutation and thus this mutation
is likely not a genetic cause for ACH.
FGFR3 phosphorylation levels determine the severity of
dwarfism phenotypes
It has been suggested that there is a correlation between the
level of FGFR3 phosphorylation and the severity of the
disturbance in endochondrial ossification in human skeletal
dysplasias. Ornitz and colleagues were the first to explore if such
a correlation exists [23]. They compared the ligand-independent
phosphorylation of the R248C and K650E mutants, associated
with thantaophoric dysplasia type 1 (TD1), to the phosphorylation
of the G380R mutant linked to ACH. TD1 is characterized by
severe shortening of the limbs with curved femurs, large head, and
a narrow thorax with small ribs [11,22]. It is always lethal in the
neonatal period, and is thus much more severe than ACH. In the
experiments of Ornitz and colleagues, the mutations responsible
for TD1 were more activating than the ACH mutation [23]. Thus,
these experiments provided a biochemical explanation of the
severity of the two phenotypes.
A study by Bellus at al [46] compared the ligand-independent
phosphorylation of FGFR3 mutants implicated in (i) thanatopho-
ric dysplasia type 2 (TD2), (ii) severe achondroplasia with
developmental delay and acanthosis nigricans (SADDAN), and
(iii) hypochondroplasia (HCH). The clinical features of TD2 are
similar to the clinical features of TD1, but the femurs in TD2 are
straight. SADDAN patients have very short stature with very short
limbs, and exhibit developmental delay and intellectual disability.
The features of HCH, which occurs in 1 in 15,000 to 40,000
newborns, are milder than ACH. The work of Bellus compared
the ligand-independent activity of FGFR3 carrying three different
mutations: the K650E mutation linked to TDII, the K650M
mutation causing SADDAN, and the K650N and K650Q
mutations associated with hypochondroplasia. They found that
the phosphorylation of the TD2 and SADDAN mutants was much
higher than that of the HCH mutants, which in turn was higher
than the phosphorylation of the wild-type [46].
In a third study, Adar and colleagues compared the effects of
the G370C and G371C mutations linked to TD1, to the effect of
the ACH G375C mutation [19]. The G370C and S371C mutants
produced higher levels of constitutive activation of MAPK in L8
cells and c-fos transcription in RCJ cells than the G375C mutant,
consistent with the fact that TD1 is much more severe than ACH.
All these data suggest that a relationship exists between the
activity levels of the mutants and the severities of the associated
disorders. Here we seek insight into how different FGFR3 mutations
cause the same dwarfism phenotype, and we thus compare the
phosphorylation of two mutants linked to the same phenotype,
ACH. Unlike previous comparisons, here we compare the
phosphorylation over a wide range of ligand concentration, and
we perform cross-linking experiments within the native cellular
membrane in order to probe the underlying cause for the elevated
phosphorylation due to the mutations. We observe identical
behaviors of the G380R and G375C mutants in terms of their
activities and cross-linking propensities. These data are consistent
with the idea that the severity of the phenotype is directly linked to
the degree of RTK phosphorylation.
Yet, the phosphorylation level of a particular mutant is not the
only determinant of a pathological phenotype. For instance, the
A391E mutation in FGFR3 increases FGFR3 phosphorylation at
low ligand concentration, similarly to the G380R and G375C
ACH mutations studied here [31]. However, the A391E mutation
causes a distinctly different phenotype, Crouzon Syndrome with
Acanthosis Nigricans, a disorder which impacts predominantly the
cranial bones and the skin [47], not the long bones. It has been
shown that the A391E mutation increases FGFR3 dimerization
[16,31,40], unlike the G380R and G375C mutations. Thus, both
the level of kinase activity, and the physical-chemical and
structural determinants of the kinase activity, determines a specific
pathological phenotype.
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